MedTrace Logo

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

NCT01013675 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 622

Last updated 2011-10-27

No results posted yet for this study

Summary

A controlled, double-blind study to determine the immunogenicity and safety of influenza cell derived vaccine in elderly subjects.

Conditions

  • Influenza Vaccines

Interventions

BIOLOGICAL

Influenza Vaccine

surface antigen, inactivated, prepared in cell cultures

BIOLOGICAL

Influenza Vaccine

surface antigen, inactivated, prepared in egg (influvac ®)

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Abbott Biologicals

    lead INDUSTRY

Principal Investigators

  • Hanka de Voogd, MD · Abbott Healthcare Products B.V

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
61 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Czechia
  • Estonia
  • Lithuania

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01013675 on ClinicalTrials.gov